Skip to main content

Table 1 Clinical characteristics

From: Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease

  Overall (n = 38) IBD (n = 12) No IBD (n = 26)
Age, median (range) 53.1 (21.9–82.7) 27.6 (23.3–74.9) 58.3 (21.9–82.7)
Sex distribution (% female) 81.6 66.7 88.5
BMI, kg/m2 median (range) 24.8 (14.9–39.9) 25.6 (18.5–30.3) 23.8 (14.9–39.9)
Number prior CDI episodes, median (range) 5 (3–13) 4.5 (3–7) 5 (3–13)
Number prior metronidazole courses, median (range) 1 (0–8) 1 (0–2) 1 (0–8)
Patients treated with at least one prior course of metronidazole, n (%) 33 (86.8%) 9 (75%) 24 (92.3%)
Number prior vancomycin 10–14 day courses, median (range) 2 (0–4) 2 (0–4) 2 (0–3)
Patients treated with at least one prior course of vancomycin, n (%) 36 (94.7%) 11 (91.7%) 25 (96.2%)
Number prior vancomycin tapers, median (range) 1 (0–5) 1 (0–1) 1 (0–5)
Patients treated with at least one prior course of vancomycin taper, n (%) 26 (68.4%) 7 (58.3%) 19 (73.1%)
Number prior fidaxomicin courses, median (range) 0 (0–4) 0 (0–2) 0 (0–4)
Patients treated with at least one prior course of fidaxomicin, n (%) 16 (61.5%) 5 (41.7%) 16 (61.5%)
Related donors, n (%) 12 (31.6%) 0 (0%) 12 (46.2%)
Recurrent CDI within 24 months of FMT, n (%) 5 (13.2%) 3 (25%) 2 (7.7%)